NIVF stock forecast, quote, news & analysis
NewGenIvf Group Ltd is a tech-forward, diversified, multi-jurisdictional entity capitalizing on emerging opportunities across real estate development, digital asset innovation, and reproductive health solutions... Show more
Why NewGenIvf Group (NIVF) Stock Is Down 92% in the Last 30 Days
Key Takeaways
- NewGenIvf Group shares fell roughly 92% over the trailing 30 days, sliding from about $1.21 in early September to near $0.10 per share.
- The selloff was driven by a 1-for-3 reverse stock split and a deeply discounted $1.25 million public offering priced at $0.07 per share.
- NewGenIvf is pivoting beyond its core fertility services business into AI, holding a 13% stake in K25.ai and advancing a cell-sorting (cytometry) platform.
- Four reverse stock splits executed during 2026 underscore ongoing Nasdaq listing-compliance and capital-raising pressure.
- A single-session plunge of roughly 77% followed the company's announcement of the dilutive offering in late September.
NewGenIvf Group (NIVF) Company Overview and Market Position
NewGenIvf Group Limited is a fertility-services provider headquartered in Bangkok, Thailand, operating assisted reproductive clinics and related services in Thailand, Cambodia, Hong Kong, and Kyrgyzstan. The company offers in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), embryo culture, egg freezing, sperm analysis and sorting, chromosomal screening, and surrogacy and ancillary care services. Founded in 2011, NewGenIvf trades on the Nasdaq Capital Market under the ticker NIVF.
In recent periods the company has positioned itself as a technology-driven, diversified growth platform, expanding beyond traditional fertility care into artificial intelligence and biomedical equipment. Its strategic investments include a 13% equity stake in K25.ai, an AI-focused venture, and the development and deployment of Nodexus cell-sorting machines through an advanced cytometry platform. Investors follow NIVF both for its core reproductive-health operations and for this emerging AI and med-tech pivot, although the company's micro-capitalization and repeated capital-raising activity make the stock exceptionally volatile.
NewGenIvf Group (NIVF) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, NIVF shares have collapsed by approximately 92%, falling from a closing price near $1.21 in early September to roughly $0.10 per share. The decline accelerated in late September, when the stock dropped from about $0.34 to below $0.08 in a matter of sessions before paring some of those losses.
The picture over the trailing quarter is even steeper. Around late July, NIVF traded near $2.60 per share on a split-adjusted basis. By early October, the stock had fallen to the $0.10 level, a decline of roughly 96% over that span. The trend has been consistently downward, punctuated by sharp single-day drops tied to corporate actions and financing announcements rather than a gradual, orderly repricing.
What Drove NIVF Stock Price in the Last 30 Days
The most significant catalyst over the last 30 days was a 1-for-3 reverse stock split that took effect on September 1, 2026. Reverse splits are frequently used by companies to lift a low share price and regain compliance with exchange minimum-bid requirements, but they do not change a company's underlying market value, and shares often come under renewed selling pressure afterward.
The decisive trigger, however, was the September 29 announcement that NewGenIvf had priced a public offering expected to generate approximately $1.25 million in gross proceeds. The offering consisted of roughly 17.86 million common shares or pre-funded warrants priced at $0.07 per share, a steep discount to the prevailing market price at the time. The deeply dilutive terms reflected weak investor demand, and the stock fell about 77% in a single session in response. NewGenIvf said it intended to use the proceeds, together with existing cash, to invest in K25.ai, restructure debt, manufacture and deploy Nodexus cell-sorting machines, and fund working capital and general corporate purposes. Aegis Capital acted as exclusive placement agent.
What Drove NIVF Stock Performance Over the Last Quarter
The quarterly decline reflects a longer-running pattern of reverse splits and equity financing. During 2026, NewGenIvf executed four reverse stock splits, effective in January, March, July, and September, as management worked to sustain the share price above Nasdaq's minimum-bid threshold. These actions, combined with a series of share issuances and a convertible-note exchange completed in August, have steadily diluted existing shareholders and weighed on sentiment.
At the same time, the company has been repositioning itself around artificial intelligence. Management has highlighted its K25.ai investment and the Nodexus cytometry platform as growth initiatives, but these ventures have not yet offset the fundamental pressures of a small, capital-constrained business. The result has been persistent downward pressure on the share price, punctuated by the late-September financing that pushed the stock to multi-year lows.
Trending AI Robots
For investors seeking a data-driven approach to volatile micro-cap names like NIVF, Tickeron's Trending AI Robots page offers a curated view of algorithmic trading strategies. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of tickers, but only the top-performing and most relevant bots are featured in this section. These bots vary widely in strategy, timeframe, and performance metrics, allowing users to explore approaches that align with different risk tolerances and trading styles. The page is designed to help traders identify AI-driven signals and tools that match current market conditions without recommending any specific security.
NIVF Stock Forecast Drivers: What Investors Should Watch Next
Several factors are likely to shape NIVF's share price going forward. Investors should monitor whether the company completes its offering and deploys the proceeds into K25.ai and the Nodexus cell-sorting platform as planned, and whether those initiatives generate measurable revenue or valuation support. Nasdaq listing compliance remains a key risk, given the company's history of reverse splits and its sub-$1 share price.
Further capital raises are a central concern, as additional dilution could pressure the stock. Financial results and any updates on debt restructuring, the commercialization of the cytometry platform, and the performance of the K25.ai stake will also be important. Broader investor appetite for speculative micro-cap and AI-adjacent equities may influence sentiment. As with any small-cap security experiencing this level of volatility, the risk of further substantial price swings remains high.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
NIVF's Stochastic Oscillator sits in oversold zone for 20 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
Following a +13.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where NIVF advanced for three days, in 66 of 78 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
NIVF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NIVF as a result. In 38 of 38 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for NIVF turned negative on September 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 10 similar instances when the indicator turned negative. In 10 of the 10 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
NIVF moved below its 50-day moving average on August 26, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NIVF declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for NIVF entered a downward trend on October 01, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.031) is normal, around the industry mean (208.195). P/E Ratio (0.001) is within average values for comparable stocks, (175.456). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.005) is also within normal values, averaging (2.688).
The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 99 (best 1 - 100 worst), indicating slightly worse than average price growth. NIVF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NIVF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry HospitalNursingManagement